1 citations
,
January 2012 in “Daehan namseong gwahag hoeji” Dutasteride is more effective than Finasteride in reducing prostate size and PSA levels, but both drugs have similar side effects.
1 citations
,
April 2010 in “Cancer Research” WYE-130600 may cause skin thickening and irritation.
1 citations
,
January 2003 in “Expert Opinion on Therapeutic Patents” Steroid sulfatase inhibitors could potentially treat hormone-related disorders like certain cancers, hair loss, acne, and improve cognitive dysfunction.
1 citations
,
September 2001 in “PubMed” ONO-3403 effectively reduces mouse skin tumor growth without side effects.
1 citations
,
March 1997 in “Journal of Chromatography B: Biomedical Sciences and Applications” Researchers developed a method to measure different forms of a drug that could help treat prostate issues and hair loss, and found how these forms behave in animals.
June 2026 in “Frontiers in Medicine” 5α-reductase inhibitors for hair loss can cause mild, reversible sexual side effects in some men.
June 2026 in “Pharmaceuticals” 5α-Reductase inhibitors, like finasteride, can cause serious, persistent side effects not always listed in official drug information.
June 2026 in “The Journal of Sexual Medicine” Finasteride may be linked to more psychiatric issues than dutasteride, but a definite cause isn't proven.
May 2026 in “Frontiers in Pharmacology” Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.
Finasteride and dutasteride can harm male reproductive health, affecting sperm and causing sexual dysfunction.
April 2026 in “The Journal of Steroid Biochemistry and Molecular Biology” April 2026 in “Journal of the American Academy of Dermatology” Oral 5-alpha-reductase inhibitors for hair loss don't increase heart risk.
March 2026 in “Frontiers in Bioscience-Elite” Duloxetine, escitalopram, and finasteride may be effective against bacteria and fungi.
March 2026 in “Mendeley Data” Janus kinase inhibitors help hair regrowth in kids with alopecia areata but need more safety research.
March 2026 in “Journal of Clinical Oncology” Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
February 2026 in “Postgraduate Medicine” 5-alpha reductase inhibitors slightly increase depression risk, but the risk varies based on the control group used.
February 2026 in “Case Reports in Dermatology” Finasteride can cause melasma, especially in people with darker skin.
February 2026 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
January 2026 in “International Journal of Molecular Sciences” Hedgehog pathway inhibitors could be effective in treating melanoma.
January 2026 in “Journal of the American Academy of Dermatology” 5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.
January 2026 in “Yonsei Medical Journal” Finasteride and dutasteride have little effect on Type 2 Diabetes risk.
January 2026 in “Figshare” Finasteride can cause melasma, especially in people with darker skin.
January 2026 in “Figshare” Finasteride can cause melasma, especially in people with darker skin.
January 2026 in “Open Science Framework” Oral and topical 5-alpha reductase inhibitors affect DHT levels and hair density differently in treating hair loss.
December 2025 in “International Neurourology Journal” Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.
December 2025 in “Molecules” DPP may help hair regrowth by improving blood vessel function under stress.
December 2025 in “Instituto Politécnico do Porto” Patients with mood disorders using 5α-reductase inhibitors may have a higher risk of suicidal thoughts.
December 2025 in “Cureus” Using 5α-reductase inhibitors for hair loss may increase the risk of dry eye disease.
December 2025 in “Biomedicines” Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.
December 2025 in “Педиатрическая фармакология” Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.